A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes

Area of Science:

• Oncology
• Endocrinology
• Epidemiology

Background:

• Pancreatic ductal adenocarcinoma (PDA) is frequently preceded by diabetes mellitus.
• Early PDA diagnosis is possible through screening individuals with new-onset diabetes.

Purpose of the Study:

• To develop and validate a Pancreatic Ductal Adenocarcinoma (PDA) risk prediction model.
• To identify high-risk individuals among those with new-onset diabetes for earlier PDA detection.

Main Methods:

• Retrospective cohort study using a UK population representative database.
• Included individuals aged >35 with incident diabetes and ≥3 years follow-up.
• Developed a risk model using backward stepwise selection of clinical and epidemiological predictors.

Main Results:

• Analyzed 109,385 patients; 390 (0.4%) diagnosed with PDA within 3 years.
• The final model (AUC 0.82) included age, BMI, smoking, PPI use, medications, HbA1C, lipids, creatinine, and alkaline phosphatase.
• A 1% risk threshold identified 6.19% of patients for screening, with 44.7% sensitivity and 94.0% specificity for PDA.

Conclusions:

• A risk prediction model using accessible clinical parameters was developed.
• This model aids in identifying new-onset diabetes patients who may benefit from Pancreatic Ductal Adenocarcinoma (PDA) screening.